CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
NanoBiCar aims to transform bacterial infection treatment through innovative immunotherapy targeting both intracellular and extracellular bacteria. Using tuberculosis as a model, the project explores mRNA encapsulated in lipid nanoparticles to enhance immune responses without contributing to antibiotic resistance.
It is estimated that 20% of global mortality is associated with bacterial infections.
The current treatment is based on the use of antibiotics, but nonspecific effects, difficulty in reaching intracellular bacteria, and the generation of antimicrobial resistance limit its effectiveness.
Tuberculosis (TB) is the leading cause of mortality due to a single infectious agent:
Mycobacterium tuberculosis (Mtb).
Multidrug-resistant TB (MDR-TB) is a major threat to global health security. A quarter of th…
UNIVERSITAT POLITECNICA DE VALENCIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Israel, Haifa
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
